Characterizing Loss of Response in Patients During Long-Term Maintenance Therapy with Baricitinib: Results From BRAVE-AA1 and AA2 Trials
January 2025
in “
SKIN The Journal of Cutaneous Medicine
”
Studysummary This study of baricitinib in adults with severe alopecia areata found that after initial success, 10.9% of participants lost treatment response by Week 152. Factors like longer disease duration and severe baseline symptoms were more common in those losing response.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on skin.dermsquared.com →